Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
In this issue:
› Topical tacrolimus (Protopic) and pimecrolimus (Elidel): potential cancer risk
› Duloxetine (Yentreve, Cymbalta): need for monitoring
› Tenofovir (Viread): interactions and renal adverse effects
› Linezolid (Zyvox): severe optic neuropathy
› CosmoFer and high risk of anaphylactoid reactions
› Drotrecogin alfa (activated) (Xigris): risk-benefi t in the management of sepsis
› Rosuvastatin (Crestor): introduction of 5 mg starting dose
› Osteonecrosis of the jaw with bisphosphonates
› High dose inhaled steroids: new advice on supply of steroid treatment cards
› Local reactions associated with pre-school d/DTap-IPV boosters
› Salmeterol (Serevent) and formoterol (Oxis, Foradil) in asthma management
› Risk of QT interval prolongation with methadone
› Tamsulosin (Flomax) and Intraoperative Floppy Iris Syndrome (IFIS)
› Cardiovascular safety of NSAIDs and selective COX-2 inhibitors
› Erythromycin and other macrolides: focus on interactions
› Glucosamine adverse reactions and interactions
› Isotretinoin (Roaccutane): psychiatric adverse reactions
› Cardiac arrhythmias associated with antipsychotic drugs
› HRT and tibolone (Livial): update on the risk of endometrial cancer
› Hypoglycaemia unawareness on transferring insulins
› Withdrawal of co-proxamol
› Intravenous human normal immunoglobulin (IVIg) and thromboembolic adverse reactions
› NSAIDs and infertility
› Patients across the UK may report suspected adverse reactions
Current Problems in Pharmacovigilance: Volume 31, (Pages 1-12) May 2006 
